Canada markets open in 5 hours 11 minutes

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.82+0.84 (+6.01%)
At close: 04:00PM EDT
15.56 +0.74 (+4.99%)
After hours: 07:25PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • K
    Kardelen
    MASSIVE order are coming in at the close, huge volume. Large institutions on the move again🤑🚀
  • C
    Chetan
    Pfizer/Moderna got approval for their booster dose after trying it on rats. Why Arcturus shouldn’t get approval for their booster dose after reporting positive data in humans? Does FDA think rats are more import than humans?
  • C
    Chetan
    After a long delay Phase 2 trial for ARCT-810 is under way. Will we get any update on the trial result before the end of the year? I doubt it but if we get any positive news during 1H2023 then it can be a catalyst for the stock.

    https://clinicaltrials.gov/ct2/show/NCT05526066?lead=Arcturus&draw=2&rank=1
    Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 - Full Text View.
    Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 - Full Text View.
    clinicaltrials.gov
  • R
    Rhobo
    $MRNA & $ARCT taking a hit from Biden's statement that "pandemic is over". Meanwhile, covid booster components will likely become part of annual flu shots that persons over 50 should be taking.
  • C
    Chetan
    Finally some good news about getting some funding from BARDA to develop influenza vaccine. This gives me some confidence in the company going forward.

    Interesting though is the fact that BARDA is funding development of influenza vaccine which is not even in pre-clinical development yet, but company can’t get any funding from BARDA to develop ACT-154 booster dose for treatment of COVID.
  • R
    Rhobo
    Data looks good. Whether good enough to garner govt approvals anywhere, we still need to see.
  • H
    Henry
    Does anyone know,

    In this bifurcated booster study supposedly to begin in Q4 (I assume that Q4 means that on December 28, 2022 Dysfunctional will announce that dosing for the study will begin "soon", In Payne time soon means July 2023). Is the ineffective ARCT dose in the syringe going to be reconfigured for the most prevalent variant at the time, or will the bifurcated booster dose continue to target BA.1 and BA.2?

    I can not find any statement on this subject.

    December 28, 2022 will be a down day for ARCT. I predict down 15% that day. We will see.
  • C
    Chetan
    ARCT reported six month durability data today for Omicron variants and it is looking good. Now they need to start their global booster trial for ARCT-154 to confirm this data.

    So far Payne has delivered on his promise to report six month durability data. ARCT is well positioned for 2023. Partnership with BP is forth coming. I stay invested in ARCT.
  • s
    sauve
    30 days - moderna - mRNA 1273.214 - ba4/ba5 - gmfr 6.3 - titer 776
    29 days - arcturus - ARCT-154 - ba5 - gmfr 33 - titer 295-730
    above is my comparison based on new data from Moderna and Arcturus, now all I have to do is discover what it means ha-ha
  • C
    Chetan
    Very low volume. Not much interest in this stock right now. This stock wants to go down unless Payne gives some surprising good news. Company needs to raise more cash in difficult environment unless it finds BP partner.
  • P
    Plugged In Profits
    https://daytradingz.tips/Limited-Time-Offer
  • C
    Chetan
    Payne continues in his old habit of missing his own guidance.

    (1) CF has been further pushed back from his revised delayed guidance of 3Q2022 to 4Q2022.

    (2) Still there is no indication that they have dosed their first patient in Phase 2 trial of OTC. That should have occurred before the end of 2Q2022 as per his revised guidance.

    (3) EUA for ARCT-154 has been delayed from 1Q2022 as per his initial guidance to now 4Q2022.

    (4) Initiation of global Phase 3 trial for booster dose of ARCT-154 should have occurred before the end of 2Q2022. New he is guiding that it will happen in 4Q2022.

    In spite of all the delays, I still remain hopeful of the long term prospect of the company. ACT-154 continues to produce excellent clinical data. But timing is critical. Revenue for 2Q far exceeded my expectation. What will be the revenue for 3Q? It seems BP is interested in the company. Buyout of the company for over $100 is possible if Payne executes on his promises and biotech sector recovers. I will wait for couple of years for the ultimate reward.
  • C
    Chetan
    Near term catalysts that can drive ARCT further up:-

    (1) ARCT-154 EUA in Vietnam
    (2) Positive six month booster durability data for Omicron variants.
    (3) Initiation of Phase 3 booster trial
    (4) CTA filing for CF.
    (5) Positive top line Phase 2 data for OTC

    If Payne delivers on all these milestones then stock will be well over $30 by the end of the year. Next year is looking good for ARCT. Very likely that company will be bought out by the end of next year.
  • l
    li ming
    Good Q2 results but stock get downgraded.
    Delays in its arct154 and other programs are not unexpected. More importantly, the data and results from its ongoing trials should be the key focus. That being said I believe this stock is still very much in the hands of short sellers and they will continue to hammer the stock to make money.
  • H
    Henry
    This moderate volume build in price over the last few weeks is consistent with inside trading. These 200-300 employee companies, everyone knows what is going on, also, in this case, ARCT is dealing with corrupt regulatory agencies and health organizations. Problem is, is that I just can't imagine this management group being able to succeed in anything.

    CF is 2023-24, OTC could have some enrollment news. Ultragenyx no relevant ARCT news.

    NVAX is interesting today. The recent change in the World Bank's vaccine commitments is puzzling.

    All hugs and kisses here.
  • A
    Adam
    Massive beat on EPS, -0.83 vs -1.88. New trials for global booster is the right direction to take. More expenses since they wouldn't be funded, but the have the secret sauce of vaccines. Curious what upgrades/downgrades analysts will release rest of the week.

    If down short term, long term winner here.
  • A
    Adam
    earnings beat, react like GRTS last few days.
    earnings miss, react like NTLA last early this week.
    I'm glad to see it's not a dead company...just been put on the shelf last few weeks.
  • A
    Adam
    CFO bought ARCT, almost $20k couple days ago. Bought the dip. Not much, but nice to see insider acquisitions on the common market no less...low price of ~$18.50 due to 'employee stock purchase plan'.
    How many people buy this stock and watch it tank. lol well, good for him...and us holders.
    Now that Bed Bath and Beyond is taking a dump, maybe markets will resume their normally scheduled rally to keep us out of the stinking bear market.
  • A
    Adam
    lol, yes, sell news of the only vax to hold 6 months stable antibody response. this is comical.

    Some context...

    Vietnam vax likely mandatory because their GDP is super reliant on exporting manufactured things.
    6 days ago, Samsung invested $3.3 b into chip manufacturing to offset strife from China unknowns.
    https://theprint.in/tech/samsung-to-invest-3-3-billion-in-vietnam-for-semiconductor-parts-amid-us-china-chip-war/1080153/

    Additionally, Intel has invested in VinGroup's EV business almost 2 months ago.
    https://asia.nikkei.com/Business/Technology/Intel-deal-with-Vietnam-s-Vingroup-reflects-shared-EV-ambitions
  • H
    Henry
    Yet again, someone is hitting the $25 calls. Losing bet last 2 months.

    There has been robust closing volume here for several days.

    Take it for what it is worth.